CY1115803T1 - Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα - Google Patents

Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα

Info

Publication number
CY1115803T1
CY1115803T1 CY20141101015T CY141101015T CY1115803T1 CY 1115803 T1 CY1115803 T1 CY 1115803T1 CY 20141101015 T CY20141101015 T CY 20141101015T CY 141101015 T CY141101015 T CY 141101015T CY 1115803 T1 CY1115803 T1 CY 1115803T1
Authority
CY
Cyprus
Prior art keywords
methods
vulnerable
measures
action
cellular immune
Prior art date
Application number
CY20141101015T
Other languages
Greek (el)
English (en)
Inventor
Jirina Bartunková
Radek Spísek
Original Assignee
SOTIO a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11172622A external-priority patent/EP2543386A1/en
Application filed by SOTIO a.s. filed Critical SOTIO a.s.
Publication of CY1115803T1 publication Critical patent/CY1115803T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20141101015T 2011-07-05 2014-12-05 Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα CY1115803T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
EP12734884.5A EP2691110B1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (1)

Publication Number Publication Date
CY1115803T1 true CY1115803T1 (el) 2017-01-25

Family

ID=50023029

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101015T CY1115803T1 (el) 2011-07-05 2014-12-05 Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα

Country Status (7)

Country Link
JP (1) JP6235085B2 (hr)
CL (1) CL2013003282A1 (hr)
CY (1) CY1115803T1 (hr)
HR (1) HRP20141230T1 (hr)
IL (2) IL229702A (hr)
MX (1) MX2013013243A (hr)
ZA (1) ZA201307886B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852672C (en) 2011-10-17 2021-07-20 Massachusetts Institute Of Technology A microfluidic system and method for delivering a payload into a cell by causing perturbations in a cell membrane of the cell
JP6502940B2 (ja) 2013-08-16 2019-04-17 マサチューセッツ インスティテュート オブ テクノロジー 細胞への物質の選択的送達
KR20170074235A (ko) 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달
CN113897285A (zh) 2014-11-14 2022-01-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
EP4257675A3 (en) 2015-07-09 2024-01-03 Massachusetts Institute of Technology Delivery of materials to anucleate cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases

Also Published As

Publication number Publication date
IL229702A0 (en) 2014-01-30
IL229702A (en) 2016-09-29
JP2017025066A (ja) 2017-02-02
IL247781A0 (en) 2016-11-30
CL2013003282A1 (es) 2014-10-10
JP6235085B2 (ja) 2017-11-22
ZA201307886B (en) 2015-03-25
IL247781B (en) 2019-11-28
HRP20141230T1 (hr) 2015-02-13
MX2013013243A (es) 2014-05-30

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1115803T1 (el) Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα
PH12019501959A1 (en) Therapeutic rna
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
UA111738C2 (uk) Спосіб активної клітинної імунотерапії раку шляхом застосування пухлинних клітин, знищених за допомогою високого гідростатичного тиску, і дендритних клітин
WO2014018563A3 (en) Methods for the treatment of cancer
MY195167A (en) Modified Nucleotide Linkers
NZ739133A (en) Cellular targeted active ingredient delivery system
EA201400178A1 (ru) Лечение рака молочной железы
EA201291194A1 (ru) Индолы
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
EA201891601A1 (ru) Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
EP3998341A3 (en) Adenoviral vectors
RU2012151073A (ru) Способ стабилизации раствора дигидрокверцетина
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
CY1118614T1 (el) Νεα παραγωγα (αζα)βενζυδρυλαιθερα, διεργασια παρασκευης τους και χρηση τους ως προσδετες h4-υποδοχεα για θεραπευτικες εφαρμογες
NI201200183A (es) Una combinación antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino
TH149241B (th) วิถีทาง และวิธีสำหรับแอคทีฟ เซลลูลาร์ อิมมูโนเธราปี เพื่อรักษาโรคมะเร็ง โดยการใช้เซลล์เนื้องอกซึ่งถูกฆ่าโดยแรงดันไฮโดรสแทติคระดับสูง และเซลล์เดนไดรท์